The hits keep coming for Biolase (BIOL +6%) as the USPTO issues it a new patent covering the use...
The hits keep coming for Biolase (BIOL +6%) as the USPTO issues it a new patent covering the use of its laser technologies for treating a broad range of eye conditions, including presbyopia, glaucoma, retinal disorders, and cataracts. The patent supports existing ophthalmic patents previously granted by expanding the application of the laser to include the architecture and techniques for treating an ocular or related tissue site with a measuring device capable of determining the thickness of the tissue.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs